The term glycobiology, also called as glycans, is the study of structure, function and biology of carbohydrate. They are the most essential components in living things. Merton Bernfield and colleagues discovered the first syndecans, which is a core protein with sugars attached to the cell surfaces that control or influence tissue repair, metabolism, formation of tumors and development of immune responses. Syndecan plays an important role in obesity, cancer and bacterial pathogenesis. Drugs such as heparin, erythropoietin and some of anti-flue drugs have proven effective and exhibit the importance of glycans as a new class of drugs. Not only in pharmaceuticals, glycobiology are used in various fields such as biotechnology, material science, marine science, food & beverages and many others. New technologies such as carbohydrate microarray have overcome the hurdles involved in the research in the field of glycobology by allowing high yield screening and analysis of protein-glycan interactions.
Recent progress in chemical synthesis and bioengineering which has resulted in the development of carbohydrate-based vaccines, have boosted the growth of market. Moreover, increasing R&D expenditure by pharmaceutical companies and increasing funding through government bodies have elevated the growth of the market. However, complexity in the glycan structures makes it difficult to produce large quantity of glycans, for instance, monosaccharide components have greatly different biological properties while having the same molecular composition, hence are indistinguishable by most analytical methods. Additionally, high production cost and low availability of skilled experts would restrict the growth of market. Furthermore, the search for new anti-cancer drugs and mergers and acquisition of major companies are opening up new possibilities for the market.
The glycobiology market is segmented based on the product, application, end-user and geography. Product is further segmented into instrument, kits, reagent and enzymes. Furthermore, application is segmented into oncology, diagnostics, drug discovery and development, immunology and others. Based on end-user, the market is segmented into pharmaceuticals & biotechnology companies, research institutes and contract research organizations. Additionally, based on geography, the glycobiology market is segmented into North America, Europe, Asia-Pacific and Rest of world (RoW).
The key players are Merck KGaA, Bio-Techne Corporation, Bruker Corporation, Thermo Fisher Scientific, Inc., Shimadzu Corporation, Plexera Bioscience LLC, New England Biolabs Inc., Agilent Technologies, Inc., and ProZyme, Inc.
The key takeaways from the report
- The report will provide detailed analysis of glycobiology market with respect to major segments such as product, application and end-user of the market.
- The report will include the qualitative and quantitative analysis with market estimation over 2015-2024 and compound annual growth rate (CAGR) between 2016 and 2024.
- Comprehensive analysis of market dynamics including factors and opportunities.
- An exhaustive regional analysis of glycobiology market.
- Profile of key players of the glycobiology market, which include key financials, product & services and new developments.
Scope of Glycobiology Market
- Drug Discovery and Development
- North America
- United Kingdom
- South Korea
- South America
- Middle East